ReviewHuman vaccines & immunotherapeutics2020
Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.
Review in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- In Vitro Evaluation of Antileishmanial Activity of Commiphora myrrha Essential Oil Nanoliposome.Veterinary medicine and science · 2026Article
- Peptides as a Therapeutic Alternative Against Leishmaniasis: A Scoping Review.Chemical biology & drug design · 2026Article
- Beyond the Skin: Topical Amphotericin B Nanocarriers Targeting Cutaneous Leishmaniasis with Suppression of Lymphatic Parasite Burden.Infectious disease reports · 2026Article
- Antibody response induced by structural proteins fromFrontiers in microbiology · 2026Article
- Molecular and Immunological Properties of a Chimeric Glycosyl Hydrolase 18 Based on Immunoinformatics Approaches: A Design of a New Anti-ACS pharmacology & translational science · 2025Article
- Activity-based chemoproteomic profiling reveals the active kinome ofFrontiers in pharmacology · 2025Article
- An update on recombinant vaccines against leishmaniasis.The Indian journal of medical research · 2024Review
- A New Strategy for Mapping Epitopes of LACK and PEPCK Proteins ofInternational journal of molecular sciences · 2023Article
- Article
- Article
- Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects.Pathogens (Basel, Switzerland) · 2022Review
- Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.Pathogens (Basel, Switzerland) · 2022Review
- A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines · 2022Review
- The History of Live AttenuatedPathogens (Basel, Switzerland) · 2022Review
- Review
- Overcoming roadblocks in the development of vaccines for leishmaniasis.Expert review of vaccines · 2021Review
- Inoculation of theMicroorganisms · 2021Article
- An overview of the treatment of cutaneous leishmaniasis.Faculty reviews · 2020Review
- Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4Frontiers in immunology · 2020Article
- Protective or Detrimental? Understanding the Role of Host Immunity in Leishmaniasis.Microorganisms · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The leishmaniases are a collection of vector-borne parasitic diseases caused by a number of different
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.